Aravive says Phase 3 AXLerate-OC trial did not meet primary endpoint

Aravive announced that its Phase 3 AXLerate-OC trial evaluating the safety and efficacy of batiraxcept in platinum-resistant ovarian cancer did not meet its primary endpoint of progression-free survival in the pre-specified subset of patients naive to prior bevacizumab treatment. The trial did not show any difference between the two arms in the overall populatio . The Company will continue to evaluate the complete dataset and determine next steps in the development of batiraxcept. “We are conducting additional analyses on the AXLerate-OC Phase 3 trial to further evaluate the results of this study and determine the best path forward with our two other planned indications in renal cell carcinoma and pancreatic cancer,” said Gail McIntyre, Ph.D., DABT, Aravive’s President and Chief Executive Officer. “We want to thank the patients who participated in this trial, the clinical investigators, and the Aravive team for their hard work, as we continue to pursue our goal of finding innovative cancer treatments for patients in need.”